Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 41

Sort by

Sort Order Select

Meeting Abstracts

910-P: Novel Mechanism of Action Associated with SGLT2 Inhibition, Peripheral Energy Utilization, and CV Benefits in Subjects with Type 2 Diabetes Mellitus and HFrEF

YUEJUAN QIN, NOAH D. SANCHEZ, FRANCISCA M. ACOSTA, ALEXANDER MOODY, SIVARAM NEPPALA, CURTIS L. TRIPLITT, GEOFFREY D. CLARKE, EUGENIO CERSOSIMO, RALPH A. DEFRONZO, CAROLINA SOLIS-HERRERA

Diabetes 2024;73(Supplement_1):910-P

https://doi.org/10.2337/db24-910-P

Published: 14 June 2024

View article titled, 910-P: Novel Mechanism of Action Associated with SGLT2 Inhibition, Peripheral Energy Utilization, and CV Benefits in Subjects with Type 2 Diabetes Mellitus and HFrEF

Meeting Abstracts

1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)

RALPH A. DEFRONZO, GOZDE BASKOY, CURTIS L. TRIPLITT, EUGENIO CERSOSIMO, CAROLINA SOLIS-HERRERA, JOHN M. ADAMS, II, ANDREA A. HANSIS-DIARTE, AMALIA GASTALDELLI, ALBERTO CHAVEZ

Diabetes 2024;73(Supplement_1):1550-P

https://doi.org/10.2337/db24-1550-P

Published: 14 June 2024

View article titled, 1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)

Meeting Abstracts

1667-P: Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Patients with Type 2 Diabetes (T2D)

GOZDE BASKOY, RICHARD M. PETERSON, JASON W. KEMPENICH, CURTIS L. TRIPLITT, GEOFFREY D. CLARKE, EUGENIO CERSOSIMO, MARK S. ANDREW, AURORA MEROVCI, OLGA LAVRYNENKO, ANDREA A. HANSIS-DIARTE, CAROLINA SOLIS-HERRERA, ALBERTO CHAVEZ, MARZIEH SALEHI, RALPH A. DEFRONZO

Diabetes 2024;73(Supplement_1):1667-P

https://doi.org/10.2337/db24-1667-P

Published: 14 June 2024

View article titled, 1667-P: Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Patients with Type 2 Diabetes (T2D)

Journal Articles

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects

Xi Chen, Devjit Tripathy, Robert Chilton, Andrea Hansis-Diarte, Marzieh Salehi, Carolina Solis-Herrera, Eugenio Cersosimo, Ralph A. DeFronzo

Diabetes 2024;73(6):896–902

https://doi.org/10.2337/db23-0457

Published: 21 March 2024

View article titled, Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects

Meeting Abstracts

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

YUEJUAN QIN, GOZDE BASKOY, CURTIS L. TRIPLITT, CAROLINA SOLIS-HERRERA, JOHN M. ADAMS__III, RALPH A. DEFRONZO, EUGENIO CERSOSIMO

Diabetes 2023;72(Supplement_1):124-OR

https://doi.org/10.2337/db23-124-OR

Published: 20 June 2023

View article titled, 124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

Meeting Abstracts

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

CAROLINA SOLIS-HERRERA, YUEJUAN QIN, HENRI HONKA, FRANCISCA M. ACOSTA, ALEXANDER MOODY, ALBERTO CHAVEZ, CURTIS L. TRIPLITT, GEOFFREY D. CLARKE, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2023;72(Supplement_1):99-LB

https://doi.org/10.2337/db23-99-LB

Published: 20 June 2023

View article titled, 99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

Meeting Abstracts

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

GOZDE BASKOY, YUEJUAN QIN, EUGENIO CERSOSIMO, CAROLINA SOLIS-HERRERA, JOHN M. ADAMS, III, RALPH A. DEFRONZO, CURTIS L. TRIPLITT

Diabetes 2023;72(Supplement_1):887-P

https://doi.org/10.2337/db23-887-P

Published: 20 June 2023

View article titled, 887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

Meeting Abstracts

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

ALBERTO CHAVEZ, AURORA MEROVCI, SIVARAM NEPPALA, LUIS A. CRUZ MORENO, GOZDE BASKOY, FRANCISCA M. ACOSTA, ANDREA A. HANSIS-DIARTE, CURTISS L. PUCKETT, JR., JOHN M. ADAMS, III, MUHAMMAD ABDUL-GHANI, CURTIS L. TRIPLITT, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2023;72(Supplement_1):68-LB

https://doi.org/10.2337/db23-68-LB

Published: 20 June 2023

View article titled, 68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

Meeting Abstracts

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

YUEJUAN QIN, NOAH D. SANCHEZ, ALEXANDER MOODY, FRANCISCA M. ACOSTA, SIVARAM NEPPALA, MARISSA BROWN, HENRI HONKA, LUIS A. CRUZ MORENO, CURTIS L. TRIPLITT, GEOFFREY D. CLARKE, EUGENIO CERSOSIMO, RALPH A. DEFRONZO, CAROLINA SOLIS-HERRERA

Diabetes 2023;72(Supplement_1):98-LB

https://doi.org/10.2337/db23-98-LB

Published: 20 June 2023

View article titled, 98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

Meeting Abstracts

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

YUEJUAN QIN, FRANCISCA M. ACOSTA, SIVARAM NEPPALA, TIFFANY M. CORTES, ALLISON STEPANENKO, ALEXANDER MOODY, NOAH D. SANCHEZ, MARISSA BROWN, LUIS A. CRUZ MORENO, CURTIS L. TRIPLITT, GEOFFREY D. CLARKE, EUGENIO CERSOSIMO, SARA E. ESPINOZA, RALPH A. DEFRONZO, CAROLINA SOLIS-HERRERA

Diabetes 2023;72(Supplement_1):97-LB

https://doi.org/10.2337/db23-97-LB

Published: 20 June 2023

View article titled, 97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

Meeting Abstracts

869-P: Effect of Dapagliflozin on Renal Oxygen Delivery and Consumption in T2DM and NGT Subjects

DEVJIT TRIPATHY, XI CHEN, ROBERT CHILTON, ANDREA A. HANSIS-DIARTE, MARZIEH SALEHI, CAROLINA SOLIS-HERRERA, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2023;72(Supplement_1):869-P

https://doi.org/10.2337/db23-869-P

Published: 20 June 2023

View article titled, 869-P: Effect of Dapagliflozin on Renal Oxygen Delivery and Consumption in T2DM and NGT Subjects

Meeting Abstracts

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

MARYAM BARKHORDARIAN, CURTIS L. TRIPLITT, CAROLINA SOLIS-HERRERA, JOHN M. ADAMS, III, RALPH A. DEFRONZO, EUGENIO CERSOSIMO

Diabetes 2022;71(Supplement_1):857-P

https://doi.org/10.2337/db22-857-P

Published: 01 June 2022

View article titled, 857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

Meeting Abstracts

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

ALBERTO O. CHAVEZ VELAZQUEZ, EMAD ALI, AURORA MEROVCI, CHRISTINA AGYIN, IV, TOMOKO TERASAWA, MUHAMMAD ABDUL-GHANI, CURTIS L. TRIPLITT, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2022;71(Supplement_1):644-P

https://doi.org/10.2337/db22-644-P

Published: 01 June 2022

View article titled, 644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

Meeting Abstracts

55-LB: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects

XI CHEN, CAROLINA SOLIS-HERRERA, DEVJIT TRIPATHY, ANDREA A. HANSIS-DIARTE, ROBERT CHILTON, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2022;71(Supplement_1):55-LB

https://doi.org/10.2337/db22-55-LB

Published: 01 June 2022

View article titled, 55-LB: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects

Meeting Abstracts

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

CAROLINA SOLIS-HERRERA, YUEJUAN QIN, HENRI HONKA, ALEXANDER MOODY, GEOFFREY D. CLARKE, CURTIS L. TRIPLITT, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2022;71(Supplement_1):175-OR

https://doi.org/10.2337/db22-175-OR

Published: 01 June 2022

View article titled, 175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

Meeting Abstracts

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

MICHAEL EZROKHI, ANTHONY H. CINCOTTA, EUGENIO CERSOSIMO, JOHN M. ADAMS, II, MARIAM ALATRACH, CHRISTINA AGYIN, IV, CURTIS L. TRIPLITT, NICHOLAS COMINOS, RALPH A. DEFRONZO

Diabetes 2021;70(Supplement_1):756-P

https://doi.org/10.2337/db21-756-P

Published: 01 June 2021

View article titled, 756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

Meeting Abstracts

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

MICHAEL EZROKHI, ANTHONY CINCOTTA, EUGENIO CERSOSIMO, JOHN M. ADAMS, II, MARIAM ALATRACH, CHRISTINA AGYIN, IV, CURTIS L. TRIPLITT, NICHOLAS COMINOS, RALPH A. DEFRONZO

Diabetes 2020;69(Supplement_1):1070-P

https://doi.org/10.2337/db20-1070-P

Published: 01 June 2020

View article titled, 1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

Meeting Abstracts

184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM

OLGA LAVRYNENKO, MARIAM ALATRACH, MUHAMMAD ABDUL-GHANI, EUGENIO CERSOSIMO, NAIM ALKHOURI, CURTISS L. PUCKETT, JR., RALPH A. DEFRONZO, JOHN M. ADAMS, II, JUAN A. VASQUEZ, JR., GEOFFREY D. CLARKE

Diabetes 2020;69(Supplement_1):184-OR

https://doi.org/10.2337/db20-184-OR

Published: 01 June 2020

View article titled, 184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM

Meeting Abstracts

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

MARIAM ALATRACH, CHRISTINA AGYIN, IV, JOHN M. ADAMS, II, OLGA LAVRYNENKO, NITCHAKARN LAICHUTHAI, EUGENIO CERSOSIMO, CURTIS L. TRIPLITT, AMALIA GASTALDELLI, MUHAMMAD ABDUL-GHANI, RALPH A. DEFRONZO

Diabetes 2020;69(Supplement_1):352-OR

https://doi.org/10.2337/db20-352-OR

Published: 01 June 2020

View article titled, 352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

Meeting Abstracts

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

MARIAM ALATRACH, CHRISTINA AGYIN, IV, NITCHAKARN LAICHUTHAI, OLGA LAVRYNENKO, JOHN M. ADAMS, II, MUHAMMAD ABDUL-GHANI, CURTIS L. TRIPLITT, RALPH A. DEFRONZO, EUGENIO CERSOSIMO

Diabetes 2020;69(Supplement_1):1136-P

https://doi.org/10.2337/db20-1136-P

Published: 01 June 2020

View article titled, 1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

NARROW

910-P: Novel Mechanism of Action Associated with SGLT2 Inhibition, Peripheral Energy Utilization, and CV Benefits in Subjects with Type 2 Diabetes Mellitus and HFrEF

1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)

1667-P: Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Patients with Type 2 Diabetes (T2D)

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

869-P: Effect of Dapagliflozin on Renal Oxygen Delivery and Consumption in T2DM and NGT Subjects

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

55-LB: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only